Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026

Reuters2026/08/28 09:45

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cytokinetics plans to file a supplemental New Drug Application with the FDA in Q4 2026 for aficamten in symptomatic non-obstructive HCM.
Move follows positive Phase 3 ACACIA-HCM results, meeting dual primary endpoints at 36 weeks on KCCQ-CSS and pVO
2
.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608280545PRIMZONEFULLFEED9817581) on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026

You may also like

Crypto prices